#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials
Breakpoints
00:00
Valgan Cycle of Your Isn't a Med That's Necessarily Easy to Access.
The efficacy held for all subgroups, including those receiving lymphocyte depleting induction. There were significantly more adverse events for patients treated with valgan cycle of your 37% developed leukemia versus 11.3% in the La Terma Vier arm. The neutropenia was 16.5% versus 2.7%. And two times as many patients ended up needing GCSF to treat this adverse event. I just, to me, these are absolutely practice changing data.
Transcript
Play full episode
